Indivior Pharmaceuticals (INDV) Receivables (2021 - 2026)

Indivior Pharmaceuticals' Receivables history runs 6 years deep, the most recent figure standing at $273.0 million for Q1 2026.

• In Q1 2026, Receivables rose 12.35% year-over-year to $273.0 million; the TTM figure through Mar 2026 stood at $273.0 million (up 12.35% YoY), while the FY2025 annual figure was $255.0 million, changed 0.39% from the prior year.
• Receivables was $273.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $255.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $273.0 million in Q1 2026 to a low of $220.0 million in Q4 2022.
• Historically, Receivables has averaged $250.1 million across 5 years, with a median of $255.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Receivables increased 15.91% in 2023, then decreased 0.39% in 2025.
• A 5-year view of Receivables shows it stood at $220.0 million in 2022, then increased by 15.91% to $255.0 million in 2023, then advanced by 0.39% to $256.0 million in 2024, then fell by 0.39% to $255.0 million in 2025, then rose by 7.06% to $273.0 million in 2026.
• The last three Receivables figures came in at $273.0 million (Q1 2026), $255.0 million (Q4 2025), and $259.0 million (Q3 2025), per Business Quant data.